We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
A recent UK High Court decision (Porton Capital Technology Funds and others v 3M) relating to the sale of Acolyte Biomedica Limited has provided UK M&A practitioners with a valuable insight into how the courts interpret the future obligations of the parties under an earn-out clause in a share purchase agreement
